H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Silence Therapeutics to $75 from $80 and keeps a Buy rating on the shares post the Q3 report. The company is making steady progress with lead candidates in cardiovascular disease and rare blood cancer to provide a regular cadence of clinical data in 2024, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLN: